The NM_213599.3: c.2288A>G variant in CAPN3 is a missense variant expected to cause the substitution of tyrosine with cysteine at position 763, p.(Tyr763Cys). This variant has been identified in at least six individuals with features consistent with LGMD (PMID: 16816913, 32994280, 33963534, 30564623; LOVD CAPN3_000119), including in a homozygous state without reported consanguinity in two unrelated patients (1.0 pt; PMID: 33963534, 30564623; LOVD Individuals #00361984, #00220100). It has also been reported in unconfirmed phase with a pathogenic variant in two patients (c.1621C>T p.(Arg541Trp), 0.5 pts, PMID: 32994280, LOVD Individual #00311254; c.2243G>A p.(Arg748Gln), 0.5 pts, PMID: 30564623, LOVD Individual #00220339) (PM3_Strong). At least one patient with this variant and a second presumed diagnostic CAPN3 allele had progressive pelvic girdle muscle weakness and absent calpain-3 protein expression in skeletal muscle, which is highly specific for CAPN3-related LGMD (PMID: 1681691; PP4_Strong). The upper bound of the 95% confidence interval (95% CI) of the Grpmax variant allele frequency in gnomAD v4.1.0 is 0.000007757 (4/1179962 European (non-Finnish) chromosomes, which is less than the threshold of 0.0001 (PM2_Supporting). The computational predictor REVEL gives a score of 0.93, which exceeds the VCEP threshold of ≥0.70, evidence that correlates with impact to ANO5 function (PP3). In summary, this variant meets the criteria to be classified as Pathogenic for autosomal recessive limb girdle muscular dystrophy based on the ACMG criteria applied, as specified by the LGMD VCEP (specifications version 2.0.0; 02/26/2026): PM3_Strong, PP4_Strong, PM2_Supporting, PP3.